CEO: Magnus Kjellberg
Head office: Stockholm, Sweden
Acquisition year: 2015
Industry: Specialty pharma / Animal health
Global specialty pharma company dedicated to improve the health of dogs, cats and horses
Nextmune is a science driven, global specialty pharmaceutical company dedicated to improve health for dogs, cats and horses.
Nextmune was created by Fidelio through the acquisitions and mergers of seven companies in the Netherlands, Spain, Belgium, Norway and the U.S. between 2015 and 2018.
The company is #1 globally within the growing market for allergy diagnostics and treatment (more than 95% white space remaining).
Nextmune has the only licensed immunotherapy in Europe, sells its products to more than 78 countries, has over 15,000 veterinary clients and has licensed production facilities in the U.S. and Europe.
We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune. Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner.Read more